Rytelo (Imestat): First Inhibitor Offers New Hope For Patients With Transfusion-Dependent MDS
On June 6, 2024, the U.S. Food and Drug Administration (FDA) granted approval for Rytelo™…
News
Qelbree: A Drug That Brings New Hope For Specific Needs
Recently, Qelbree has attracted a lot of attention in the pharmaceutical field.Qelbree focuses on specific…
Revuforj: New Hope For Patients With Acute Leukaemia
On 15 November 2024, the US Food and Drug Administration (FDA) approved a new drug…
Novartis Zolgensma Gene Therapy Has Significant Long-Term
Zolgensma (onasemnogene abeparvovec), Novartis’ gene therapy for spinal muscular atrophy (SMA), recently announced landmark long-term…
Rezolsta For Adolescent HIV Patients To Further Optimise Antiretroviral Regimens
The European Commission (EC) has approved an expansion of the indication for the anti-HIV combination…
Rylaze Receives FDA Approval: A Key Treatment Option For Patients With Acute Lymphoblastic Leukaemia
FDA Approval Of Rylaze Fills Asparaginase Shortage Gap, Offers New Hope For ALL/LBL Patients In…
Ravicti: Urea Cycle Disorders—Development, Clinical Results, Market Growth, and Patient Impact
Amidst the continuous progress in the field of medicine, Ravicti (glycerol phenylbutyrate), an innovative drug,…
Soliris: A Revolutionary Breakthrough In The Treatment Of Rare Diseases
In the medical field, Soliris (eculizumab) is undoubtedly a shining star, which brings unprecedented hope…
Myalepta (Metreleptin): New Hope For Patients With Lipodystrophy
Myalepta (generic: metreleptin), the first approved leptin replacement therapy, is offering new hope for these…
Luxturna Gene Therapy: New Hope For Patients With Hereditary Vision Loss
Luxturna (generic name: voretigene neparvovec-rzyl) is the first gene therapy approved by the U.S. Food…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights